Back to Journals » Hepatic Medicine: Evidence and Research » Volume 2

Potential treatment options and future research to increase hepatitis C virus treatment response rate

Authors TenCate V, Sainz Jr B, Cotler SJ, Uprichard S

Published 1 October 2010 Volume 2010:2 Pages 125—145

DOI https://doi.org/10.2147/HMER.S7193

Review by Single-blind

Peer reviewer comments 4


Veronica TenCate, Bruno Sainz Jr, Scott J Cotler, Susan L Uprichard
Department of Medicine, Section of Hepatology, University of Illinois at Chicago, Chicago, IL, USA

Abstract: Hepatitis C virus (HCV) is a liver-tropic blood-borne pathogen that affects more than 170 million people worldwide. Although acute infections are usually asymptomatic, up to 90% of HCV infections persist with the possibility of long-term consequences such as liver fibrosis, cirrhosis, steatosis, insulin resistance, or hepatocellular carcinoma. As such, HCV-associated liver disease is a major public health concern. Although the currently available standard of care therapy of pegylated interferon α plus ribavirin successfully treats infection in a subset of patients, the development of more effective, less toxic HCV antivirals is a health care imperative. This review not only discusses the limitations of the current HCV standard of care but also evaluates upcoming HCV treatment options and how current research elucidating the viral life cycle is facilitating the development of HCV-specific therapeutics that promise to greatly improve treatment response rates both before and after liver transplantation.

Keywords: interferon, STAT-C, combination therapy, personalized therapy, emerging drug targets, viral life cycle

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]